Predictors of real‐world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone‐sensitive prostate cancer-Reference-Cited by-同舟云学术

Predictors of real‐world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone‐sensitive prostate cancer

Published:2021-03-12 Issue: Volume: Page:
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Azad Arun A.¹²³^ORCID,Tran Ben¹⁴,Davis Ian D⁵⁶,Parente Phillip⁵⁶,Evans Melanie⁷,Wong Shirley⁸,Brown Stephen⁹,Evans Sue¹⁰,Millar Jeremy¹¹¹²,Murphy Declan G²¹³,Papa Nathan⁷

Affiliation:

1. Department of Medical Oncology Peter MacCallum Cancer Centre Melbourne Australia

2. Sir Peter MacCallum Department of Oncology University of Melbourne Melbourne Australia

3. School of Clinical Sciences Monash University Melbourne Australia

4. Division of Personalised Oncology Walter and Eliza Hall Institute Melbourne Australia

5. Medical Oncology Unit Eastern Health Melbourne Australia

6. Eastern Health Clinical School Monash University Melbourne Australia

7. School of Public Health and Preventive Medicine Monash University Melbourne Australia

8. Cancer Services Western Health Melbourne Australia

9. Medical Oncology Ballarat Regional Integrated Cancer Centre Ballarat Australia

10. Victorian Cancer Registry Cancer Council Victoria Melbourne Australia

11. Alfred Health Radiation Oncology Alfred Hospital Melbourne Australia

12. Central Clinical School Monash University, The Alfred Centre Melbourne Australia

13. Division of Cancer Surgery Peter MacCallum Cancer Centre Melbourne Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.15288

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CircSLC4A7 in resistant‐cells‐derived exosomes promotes docetaxel resistance via the miR‐1205/MAPT axis in prostate cancer;IUBMB Life;2024-09-12

2. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World”? A Systematic Review;European Urology Oncology;2024-02

3. Far from the truth: Real‐world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification;International Journal of Urology;2023-07-11

4. Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer;Clinical Cancer Research;2023-03-30

5. Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?;Nature Reviews Urology;2022-12-12